Abstract Purpose of Review The omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce …

There is currently growing attention being paid to the role of elevated triglycerides (TGs) as
important mediators of residual atherosclerotic cardiovascular disease (ASCVD) risk. This …

Triglyceride-rich lipoproteins (TRLs) are a source of residual risk in patients with
atherosclerotic cardiovascular disease, and are indirectly correlated with triglyceride (TG) …

Severe hypertriglyceridemia (sHTG), defined as a triglyceride (TG) concentration≥ 500
mg/dL (≥ 5.7 mmol/L) is an important risk factor for acute pancreatitis. Although lifestyle …

Over the past 40 years, there has been considerable research into the management and
treatment of atherogenic lipid disorders. Although the majority of treatments and …

Icosapent ethyl (IPE) was the first fish oil product the US Food and Drug Administration
(FDA) approved to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in …

Background: Coronary heart disease (CHD) is characterized by forming of arterial plaques
composed mainly of lipids, calcium, and inflammatory cells. These plaques narrow the …

Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3
polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs …

Abstract Omega-3 fatty acids (O3FAs) possess beneficial properties for cardiovascular (CV)
health and elevated O3FA levels are associated with lower incident risk for CV disease …

Fish oils rank among the world's most popular nutritional supplements and are purported to
have numerous health benefits. Previous work suggested that fish oils increase collagen …